Ciprobay

Uncomplicated & complicated infections caused by ciprofloxacin sensitive pathogens. Infections of the resp tract (pneumonias caused by Klebsiella spp, Enterobacter spp, Proteus spp, E. coli, Pseudomonas, Haemophilus spp, Moraxella catarrhalis, Legionella spp & Staphylococcus); middle ear (otitis media) or paranasal sinuses (sinusitis), especially if caused by gm -ve organisms including Pseudomonas or by Staphylococcus; eyes; kidneys &/or the efferent urinary tract; genital organs including adnexitis, gonorrhea, prostatitis; abdominal cavity (eg, infections of the GI or biliary tract, peritonitis); skin & soft tissue; bones & joints. Sepsis. Infections or imminent risk of infection (prophylaxis) in patients whose immune system has been weakened (eg, patients on immunosuppressants or have neutropenia). Selective intestinal decontamination in immunosuppressed patients.

IV Slowly administer infusion over 30 min. Adult Resp tract infection 200-400 mg bd. Acute, uncomplicated UTI 100 mg bd. Cystitis in women (before menopause) 100 mg as single dose. Complicated UTI 200 mg bd. Extragenital gonorrhoea 100 mg bd. Acute, uncomplicated gonorrhoea 100 mg as single dose. Diarrhea 200 mg bd. Other infections 200-400 mg bd. Severe, life-threatening infections (eg, Streptococcal pneumonia, recurrent infections in cystic fibrosis, bone & joint infections, septicemia, peritonitis) or when Pseudomonas, Staphylococcus or Streptococcus is present 400 mg tds. Renal impairment & on hemodialysis CrCl 30-60 mL/min/1.73 m² Max dose: 800 mg daily; <30 mL/min/1.73 m² Max dose: 400 mg daily; Continuous ambulatory peritoneal dialysis 50 mg/L dialysate qds.

Hypersensitivity to ciprofloxacin or other quinolones. Concurrent administration w/ tizanidine. Childn & adolescents.

Quinolones

J01MA02 - ciprofloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.

POM